Chronic Intermittent Hypobaric Hypoxia Enhances Bone Fracture Healing

Li Zhang1, Lin Jin1, Jialiang Guo1, Kai Bao2, Jinglue Hu1, Yingze Zhang1, Zhiyong Hou1* and Liping Zhang3*

1 Department of Orthopaedic Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, China, 2 Department of Orthopaedic Surgery, Hebei Provincial Hospital of Traditional Chinese Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China, 3 Department of Physiology, Hebei Medical University, Shijiazhuang, China

The effect of chronic intermittent hypobaric hypoxia (CIHH) on bone fracture healing is not elucidated. The present study aimed to investigate the role of CIHH on bone fracture healing and the mechanism. The Sprague-Dawley rats were randomly divided into the CIHH group and control group and monitored for 2, 4, or 8 weeks after femoral fracture surgery. Bone healing efficiency was significantly increased in the CIHH group as evidenced by higher high-density bone volume fractions, higher bone mineral density, higher maximum force, and higher stiffness. Histologically, the CIHH group exhibited superior bone formation, endochondral ossification, and angiogenic ability compared with the control group. The expression of HIF-1α and its downstream signaling proteins VEGF, SDF-1/CXCR4 axis were increased by the CIHH treatment. Moreover, the expression of RUNX2, osterix, and type I collagen in the callus tissues were also up-regulated in the CIHH group. In conclusion, our study demonstrated that CIHH treatment improves fracture healing, increases bone mineral density, and increases bone strength via the activation of HIF-1α and bone production-related genes.

Keywords: chronic intermittent hypobaric hypoxia, bone fracture healing, hypoxia-inducible factor-1α, mechanical properties, bone mass, callus angiogenesis, bone formation

INTRODUCTION

Bone fracture is a common clinical disease, including traumatic fracture, pathologic fracture, and periartrophic fracture. Although surgery can effectively treat the bone fracture, about 10% of fractures have impaired healing. Non-union or delayed union of fracture is still a serious public health concern (1).

Abbreviations: CIHH, chronic intermittent hypobaric hypoxia; BV, high-density bone volume; TV, total bone volume; BV/TV, the volume fractions; BMD, bone mineral density; HIF-1α, Hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; RUNX2, runt-related transcription factor.
Fracture healing is a complex physiological process, in which callus formation is a critical step for successful fracture healing (2). The overall stability of the fixation of the fracture also affects fracture healing, the more extensive cartilage tissue formation, the lower stability, and more bone tissues, the higher stability (3). Moreover, angiogenesis will be increased when fractures cannot be stably fixed (4, 5). There are several strategies to enhance fracture healing clinically (6). Commonly, it can be divided into the biophysical and biological strategy. The biophysical strategy includes electromagnetic fields and low-intensity pulsed ultrasonography (6). The biological strategy includes autologous bone marrow, peptide signaling molecules, and morphogenetic factors treatment (bone morphogenetic proteins and Wnt proteins) (6). Among them, bone morphogenetic proteins (BMPs) are the most widely studied candidate for enhancing bone repair, especially BMP-2 and BMP-7. Besides, bone morphogenetic protein 2 (BMP-2) and bone morphogenetic protein 7 (BMP-7) are the only FDA-approved therapies to promote fracture healing (7). However, BMP-2 treatment did not significantly reduce the fracture healing time of fracture patients and did not substantially promote the healing of open fractures (8, 9). Compared with autologous bone transplantation, treatment with BMP-7 did not significantly improve fracture healing (6). Also, it can cause local complications as well as serious side effects (10). Therefore, safe and effective treatment after fracture remains to be developed.

The environment has been recognized to affect the fate of bone cells, including the proliferation, differentiation, mobilization of bone progenitor cells, and the activation of mature bone cells (11, 12). Chronic intermittent hypobaric hypoxia (CIHH) is a treatment with moderate hypoxia simulating high altitude interrupted by normoxia. Studies have demonstrated that CIHH has beneficial effects on multiple organs or tissues of the body, such as the heart, brain, liver, and kidney (13–15). For example, CIHH protects heart, brain, and skeletal muscle against ischemia/reperfusion injury through enhancement of antioxidation, induction of heat shock proteins, an increase of coronary blood flow and myocardial capillary angiogenesis, activation of adenosine triphosphate (ATP)-sensitive potassium channels, and inhibition of mitochondrial permeability transition pores (16–21). Also, CIHH protects the kidneys of diabetic rats and the livers of rats with nonalcoholic fatty liver disease (22, 23). Besides, CIHH treatment decreases the arterial blood pressure in renal vascular hypertension and metabolic syndrome rats (24–26). Besides, CIHH treatment has anti-arthritis, anti-aplastic anemia, anxiolytic- and anti-depressant like effects in mice and rats (27–29). More interesting, someone reported that CIHH promotes the healing of the drilled-hole bone defect in mice (30), or has positive effects on bone mineral density in rats (31). These shreds of evidence prompted us that CIHH may promote bone fracture healing.

In the present study, the rats were exposed to CIHH conditions or normal environment for 8 weeks post-fracture, then the radiography, micro-CT assessment, biomechanical testing, immunohistochemistry, and molecular biology techniques were employed to investigate the effect of CIHH on fracture healing and the underlying mechanism. Our data indicated that CIHH treatment accelerates fracture healing via the activation of HIF-1α associated signaling pathways.

MATERIALS AND METHODS

Animals and CIHH Treatment

Adult male Sprague-Dawley rats were provided by Liaoning Changsheng Biotechnology Co., Lot. (Shenyang, Liaoning, China) with the permission number: SCXK, Liao 2015-0001. All experiments were reviewed and approved by the Ethics Committee of Hebei Medical University and carried out in compliance with the Regulatory Guideline on the Use of Experimental Animals (China, 2011).

Fracture Model and CIHH Treatment

The femoral fracture model was established as previously reported (32). In brief, an incision was made on the lateral aspect of the right thigh after anesthesia with Chloral hydrate (350 mg/kg). After the fascia, muscle, and periosteum were separated, the midshaft femoral fracture was made with a saw, and then fixed with a 1 mm Kirshner wire. Analgesia was given by subcutaneous injections of buprenorphine (50 µg/kg of body weight) 2 hours after surgery and once a day for three consecutive days. All surgical procedures were performed under strict aseptic conditions.

The rats were randomly divided into CIHH treatment (CIHH) and control groups after bone fracture surgery. As previously described (33, 34), the rats in the CIHH group were exposed to a hypobaric hypoxia chamber (Pressure: 50 kPa, oxygen concentration: 10%-11%, 22°C ± 1°C) for 6 continuous days. There are several strategies to enhance fracture healing clinically (6). Commonly, it can be divided into the biophysical and biological strategy. The biophysical strategy includes electromagnetic fields and low-intensity pulsed ultrasonography (6). The biological strategy includes autologous bone marrow, peptide signaling molecules, and morphogenetic factors treatment (bone morphogenetic proteins and Wnt proteins) (6). Among them, bone morphogenetic proteins (BMPs) are the most widely studied candidate for enhancing bone repair, especially BMP-2 and BMP-7. Besides, bone morphogenetic protein 2 (BMP-2) and bone morphogenetic protein 7 (BMP-7) are the only FDA-approved therapies to promote fracture healing (7). However, BMP-2 treatment did not significantly reduce the fracture healing time of fracture patients and did not substantially promote the healing of open fractures (8, 9). Compared with autologous bone transplantation, treatment with BMP-7 did not significantly improve fracture healing (6). Also, it can cause local complications as well as serious side effects (10). Therefore, safe and effective treatment after fracture remains to be developed.

The rats were sacrificed with over anesthesia at 2, 4, and 8 weeks post-fracture, respectively. A total of 1 cm tissues around the proximal and distal to the fracture site were collected for further analysis. For each treatment group, 6 rats were assigned to the X-radiography and micro-CT Assessment, 6 rats were assigned to the three-point bending test, 18 rats were assigned to the western blot and Real-time PCR analysis (6 in each time point), and 18 rats were assigned to the histological analysis (6 in each time point).

X-Radiography and Micro-CT Assessment

The femoral bones were photographed by a softex X-ray apparatus (Softex CSM-2; Softex, Tokyo, Japan) at week 2, week 4, and week 8 post-fracture. Femora were scanned by a micro-CT system (Bruker-microCT, SkyScan 1176, Kontich, Antwerpen, Belgium) at 8 weeks post-fracture. The scan protocol was set as follows: 18-µm isometric voxel size, 800 mA, and 80 kVp. Taking the fracture line as the midpoint reference, a total of 200 slices between the proximal and distal were analyzed. The callus was manually drawn as a region of interest, then the bone parameters of high-density bone volume
(BV), total bone volume (TV), the volume fractions (BV/TV), and bone mineral density (BMD) were analyzed with CTAn software version 1.13 (Bruker-microCT). The three-dimensional representative images were generated by CTXox software version 3.3 (Bruker-microCT).

**Three-Point Bending Test**
A three-point bending test was performed using a material testing machine (Bose 3200, Eden Prairie, MN, USA). The three bearings of the load consisted of a femoral head. After checking the position of the femur was correct, the roller stamp was driven at a speed of 5 mm/min. The pressure was monitored every 0.001 mm until fracture. We were able to analyze the elasticity, maximum force, braking force, and yield strength.

**Histological Analysis**
For hematoxylin-eosin (HE) staining, the bone callus samples were decalcified and embedded in paraffin. Then the samples were serially sectioned into 5-μm thickness. Next, the slices were stained with HE dye liquor. For Safranin O staining, the sections were p stained with Safranin O for 2 min (Solarbio, Beijing, China). Then the samples were treated in 95% ethanol for 2 min each, dewaxed twice in xylene for 10 min each. Lastly, these samples were mounted in neutral balsam (Sinopharm, Shanghai, China) and observed using a light microscope (Olympus, Tokyo, Japan).

**Immunohistochemistry (IHC)**
Paraaffin-embedded sections were mounted on slides, dewaxed, and dehydrated. After washing, slides were incubated with primary antibodies against platelet endothelial cell adhesion molecule 1 (PECAM-1/CD31, Affinity, Changzhou, Jiangsu, China), runt-related transcription factor (RUNX2, Affinity, Changzhou, Jiangsu, China), osterix (Affinity, Changzhou, Jiangsu, China), and type I collagen (Affinity, Changzhou, Jiangsu, China) overnight at 4°C, respectively. After washing with PBS, slides were incubated with a horseradish peroxidase-conjugated secondary antibody (Thermo Fisher, Cambridge, MA, USA) for 60 min at 37°C. Then these slides were stained with DAB (Solarbio, Beijing, China) and counterstained with hematoxylin (Solarbio, Beijing, China).

**Western Blot Analysis**
The proteins from the callus tissues were extracted by using lysis buffer (Beyotime, Shanghai, China). Then the protein was quantified by the BCA assay kit (Beyotime, Shanghai, China). After that, an equal amount of proteins was electrophoresed on SDS-PAGE and then transferred onto PVDF membranes (Thermo Fisher, Cambridge, MA, USA). Next, the membranes were immuno-blotted with Hypoxia-inducible factor-1α (HIF-1α) rabbit antibody (1: 500 dilution, Catalog No.: AF1009, Affinity, Changzhou, Jiangsu, China), vascular endothelial growth factor (VEGF) rabbit antibody (1: 500 dilution, Catalog No.: bs-1313R, Bios, Beijing, China), Runx2 rabbit antibody (1: 500 dilution, Catalog No.: AF5186, Affinity), Osterix (1: 400 dilution, Catalog No.: DF7731, Affinity), Type I collagen antibody (1: 1000 dilution, Catalog No.: AF7001, Affinity), SDF-1α rabbit antibody (1: 500 dilution, Catalog No.: AF5166, Affinity), CXCR4 antibody (1: 1000 dilution, Catalog No.: A12534, AbClonal, Wuhan, China), or β-actin mouse antibody (1: 2000 dilution, Catalog No.:s60008-1-lg, proteintech, Wuhan, Hubei, China). The membranes were washed three times and incubated with goat HRP-conjugated secondary antibodies (proteintech, Wuhan, Hubei, China). The specific bands were developed with the ECL system (7 Sea biotech, Shanghai, China). β-actin was used as the control of HIF-1α and VEGF.

**Real-Time PCR**
The fracture callus was collected and the total RNA was extracted by the RNApure high purity and rapid total RNA extraction kit (Biotek Corporation, Beijing, China). The cDNA was synthesized by the M-MLV reverse transcriptase (Takara, Beijing, China) in the presence of RNase inhibitor (Takara) as per the user’s manual. The quantitative real-time PCR reaction system includes 200 ng cDNA, forward primer, and reverse primer 0.2 μg each, 25 μl TaKaRa Taq™ HS Perfect Mix (Takara). The PCR was carried out on Exicycler 96 amplifier (Bioneer, Daejeon, Korea). The relative mRNA level was calculated using the 2−ΔΔCt method. The primers were as follows: HIF-1α (Forward: 5'-CTACTATGTGCTTTCTTGG-3', Reverse: 5'-GGTTTCTGCTCCGTATG-3'); VEGF (Forward: 5'-CGGACAGACAGACAGACCC-3', Reverse: 5'-AGCCCAAGTTGGAGAAAA-3'); RUNX2 (Forward: 5'-CCATAAAGGTCTTCAAAATC-3', Reverse: 5'-GAGGC GGTGACAGAGACAACT-3'); Osterix (Forward: 5'-AAAAAG GAGGCAAGAAAGAC3', Reverse: 5'-GGGAAAAAGG TGGGTAGCTAC-3'); COL1A1 (Forward: 5'-TCTTGCCGA TGTCGCTATCC-3', Reverse: 5'-TCGGTACGCATCCA CAAGC-3'); SDF-1α (Forward: 5'-GCATCAGTGAC GTAAAGC-3', Reverse: 5'-GAGGCCAGACGTGGAG-3'); CXCR4 (Forward: 5'-GGAATGGGTGGTAATC-3', Reverse: 5'- GAAATGGCAAGGATGCC-3', β-actin (Forward: 5'- GGAGATTACTGCTCCTGCTACTGCC-3', Reverse: 5'- GGCAGGACTCATGCTACTGCTGCTT-3').

**Statistical Analysis**
Data are expressed as the mean ± S.D. Statistical analyses were carried out by using Graphpad Prism 8 (GraphPad Software Inc., San Diego, CA, USA). The difference between groups was analyzed by Student’s t-test or ANOVA analysis. Differences were considered statistically significant when P < 0.05.

**RESULTS**
**Radiographic Analysis and Fracture Healing Score**
Radiographic images showed that the speed of fracture healing was faster in CIHH rats than control rats at weeks 2, 4, and 8 post-fracture (Figure 1A). Compared with control rats, the callus amount was significantly increased in CIHH rats at week 4, and the remodeling of fracture healing was almost finished in CIHH rats. Moreover, normal bone appeared at the fracture site in the
CIHH rats at week 8. The radiographic scoring of fracture healing was shown in Figure 1B. The average fracture healing score was 1.7 ± 0.5 in CIHH rats, significantly higher than 0.8 ± 0.4 in control rats at week 2 post-fracture (<0.05), and 3.2 ± 0.8 in CIHH rats, much higher than 1.3 ± 1.0 in control rats at week 4 (P<0.01). Although there was no statistical difference in fracture healing score between the two groups at week 8, the score was 4.6 ± 0.5 in CIHH rats, still higher than 3.8 ± 0.4 in the control group (P>0.05). The results revealed that CIHH treatment can increase callus production and accelerate bone fracture healing.

**Bone Mass and Mechanical Properties of Fracture Calluses**

Micro-CT scanning showed that the fracture line was clearly visible, some bone cortex is discontinuous, and the fracture end was partially hardened in the control group. On the contrary, the CIHH group exhibited a closed fracture line and healed well (Figure 2A). Further, the high-density bone volume (BV), total bone volume (TV), the volume fractions (BV/TV), and bone mineral density (BMD) were also measured by micro-CT, and the results were shown in Table 1. The TV had no statistical difference between the CIHH rats (38.6 ± 6.7 mm³) and control rats (36.2 ± 3.9 mm³) (P>0.05). The BV was 24.9 ± 3.1 mm³ in CIHH rats, much higher than 18.3 ± 1.1 mm³ in control rats (P<0.001), and BV/TV was 65.8 ± 12.5% in CIHH rats, significantly higher than 50.1 ± 3.8% in control rats (P<0.05). Moreover, the BMD was significantly increased in CIHH rats, about 4.2% higher than control rats (P<0.05). In this study, only week 8 groups were subjected to a three-point bending test as the fractured femurs at weeks 2 and 4 were too weak to test. The maximum stress was 83.6 ± 12.6 N in CIHH rats, markedly greater than 41.4 ± 3.1 N in control rats (P<0.001, Figure 2B). Although there was no statistical difference of stiffness between the two groups, the stiffness was 105.9 ± 32.1 in CIHH rats, still greater than 84.3 ± 15.0 in the control group (P>0.05, Figure 2C). These results suggested that CIHH treatment could increase the amount of highly mineralized bone and improve fracture healing.

**Histological Evaluation of Fracture**

The representative histological sections of fracture sites were shown in Figure 3. At week 4 post-fracture, the control group exhibited the domination of callus hyperplasia along with the
appearance of the woven bone, whereas a larger woven bone was developed in the CIHH group. At week 8 post-fracture, a thicker callus was formed and more woven bone was observed in control rats, while the woven bone was predominated and nearly united in the CIHH rats (Figure 3A). Safranin O staining showed that less cartilage tissue was observed in fracture calluses in CIHH rats compared with control rats at weeks 4 and 8 post-fracture (Figure 3B), indicating a better endochondral ossification process in the CIHH group.

**Angiogenesis During Fracture Healing**

The main mechanism by which cells respond to hypoxia is through the stabilization of hypoxia-inducible factor-alpha (HIF-α) proteins. Fracture healing involves angiogenesis, and vascular endothelial growth factor (VEGF) is related to HIF-1α (35, 36). In our study, we found that the protein expression levels of HIF-1α and VEGF were enhanced in CIHH rats at week 2 and week 4 when compared to the control rats (Figure 4A); however, these levels were almost the same as the control rats at week 8 post-fracture. In addition, we investigated the mRNA expression levels of HIF-1α and VEGF, and the data pointed toward the same trend. HIF-1α mRNA expression in CIHH rats was about twice as high as control rats at week 2 and week 4 (P<0.001) (Figure 4B). VEGF mRNA expression in CIHH rats was 83.0% higher than control rats at week 4 (P<0.001) (Figure 4C). Moreover, to observe the blood vessels and endothelial cells around the woven bone, we performed the IHC analysis of the vascular specific marker platelet endothelial cell adhesion molecule 1 (PECAM-1; CD31). We found that the levels of CD31 were markedly increased by CIHH treatment at weeks 2, 4, and 8 (Figure 4D). These data suggested that CIHH treatment induced an early increase in neovascularization.

**The Expression of SDF-1 and CXCR4 Axis at Fracture Sites**

The SDF-1/CXCR4 axis was reported to be regulated by the HIF-α and plays pivotal roles during progenitor homing, hematopoiesis, neovascularization, and wound healing (37). Thus, the expression of SDF-1 and CXCR4 at the fracture sites was also detected. As shown in Figures 5A–C, the protein and mRNA levels of SDF-1 and CXCR4 in the CIHH group were all higher in the control group at week 2, week 4, and week 8. These results demonstrated that the SDF-1/CXCR4 axis may be involved in CIHH induced fracture healing.

**Bone Formation**

According to the report, active osteoblasts and collagen formation were significantly increased at week 2 post-fracture (38), so we examined the levels of related factors in the callus at week 2 post-fracture. Runt-related transcription factor (RUNX2) and osterix are biochemical markers of osteoblastic differentiation and bone formation. COL1A1 gene encodes the alpha1 chain of type I collagen. The western blot results exhibited that the protein levels of RUNX2, osterix, and type I collagen were all increased by the CIHH treatment (Figure 6A). The mRNA expression of RUNX2 in CIHH rats was about twice as high as control rats (P<0.01, Figure 6B), the mRNA
expression of osterix in CIHH rats was about three times higher than that in control rats (P<0.01, Figure 6D), the mRNA expression of COL1A1 in CIHH rats was about twice as high as that in control rats (P<0.01, Figure 6F). These changes were further confirmed by immunohistochemical (Figures 6C, E, G). These findings suggested that CIHH treatment could promote osteoblastic differentiation and bone formation by the up-regulation of RUNX2, osterix, and type I collagen.

DISCUSSION

Fracture healing is a long and complex process, including initial inflammatory response, the formation of fibrocartilage, mineralization of callus, and bone remodeling (39). When a fracture occurs, the blood is interrupted at the fracture site, resulting in acute hypoxia and necrosis of the adjacent bone tissues (40). In the early stages of fracture healing, hypoxia could induce cartilage callus formation. HIF-1α is a master regulator of oxygen homeostasis, and its expression was induced by hypoxia (41). Reports claimed that increased expression of HIF-1α is observed in the early stage of bone regeneration (42, 43), suggesting that the expression level of HIF-1α is associated with fracture healing (40, 44). Our results revealed that CIHH treatment might promote fracture healing through up-regulating HIF-1α.

Angiogenesis is essential for fracture healing (45). VEGF, as the angiogenesis-related transcription and growth factor, is the key factor of angiogenesis (46). Significant reduction in angiogenesis and bone formation was observed in mice lacking HIF-1α, and the administration of VEGF receptor
antagonists can offset the angiogenesis induced by HIF-1α (47). These suggest that VEGF is one of the downstream proteins regulated by HIF-1α (48). According to reports, mice with VEGF deficiency exhibited reduced bone mass and reduced osteoblast (49), and VEGF has a direct effect on osteoprogenitor cells to enhance fracture healing (50). Also, CD31 is concentrated at endothelial cell borders, commonly used as the marker of blood vessels and endothelium (51). As the mediator of adhesion molecules and signal transduction, CD31 can enhance blood vessel formation and cell motility (52). Our research showed that CIHH may indirectly promote fracture healing by regulating angiogenesis via HIF-1α/VEGF.

SDF-1 is a member of the pro-inflammatory CXC chemokine family and plays a crucial role in cell growth, development, and differentiation via the activation of CXCR4 (53). The expression of SDF-1 and CXCR4 was significantly up-regulated in the damaged bone surrounding tissues during fracture healing (37). The SDF-1 could recruit mesenchymal stem cells and participate in endochondral bone repair (54). Knockdown of HIF-1α repressed mesenchymal stem cell migration by the blocking of the SDF-1/CXCR4 signaling (55). In the present study, the expression of SDF-1 and CXCR4 was increased along with the HIF-1α at the callosum region of the CIHH treatment rats, indicating that CIHH may contribute to the bone

**FIGURE 4 | Angiogenesis.** (A) Western blot images of HIF-1α, VEGF, and β-actin in the callus area. (B) Quantitative real-time PCR of the callus HIF-1α. (C) Quantitative real-time PCR of the callus VEGF. (D) Immunohistochemistry of CD31 within the woven bone. Magnification, x200, scale bar = 100 µm. The typical CD31-positive capillaries were indicated by arrows. n=6, Mean ± SD, ***p < 0.01.
FIGURE 5 | The expression of SDF-1 and CXCR4 axis at fracture sites. (A) Western blot images of SDF-1, CXCR4, and β-actin in the callus area. (B) Quantitative real-time PCR of the callus SDF-1α. (C) Quantitative real-time PCR of the callus CXCR4. n=6, Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001.

FIGURE 6 | Bone formation. Protein levels of RUNX2, osterix, Type I collagen (A), mRNA expression level of RUNX2 (B), osterix (D), and COL1A1 (F) of the callus area. Immunohistochemistry of RUNX2 (C), osterix (E), and type I collagen (G) within the callus area. Magnification, ×200, scale bar = 100 µm. The typical positive stained cells or regions were indicated by arrows. n=6, Mean ± SD, **p < 0.01.
formation by HIF-1α mediated activation of the SDF-1/CXCR4 signaling.

It is well known that bone development and remodeling depend on osteoblast activity. Studies have demonstrated that RUNX2 plays a key role in mammalian osteoblast development, differentiation, and bone formation (56, 57). Mice with RUNX2 deficiency showed a complete lack of bone formation (58). In addition, increased adipogenic differentiation and the loss of cartilage ossification were observed in Runx2-deficient mice (59). In contrast, overexpression of RUNX2 could promote osteogenic differentiation and enhance the rate of new bone formation (60, 61). Osterix is a transcription factor necessary for mammalian bone formation. Osterix of vertebrae is mainly expressed in osteoblasts and plays a decisive role in the later period of osteoblast differentiation (62). In osterix null mice, the cartilage develops normally, but no bone formation occurs (63). Oh et al. found that osterix is the key regulator in chondrocyte differentiation and bone growth (63). Moreover, some researchers found that osterix null mice could express RUNX2, while RUNX2/Cbfa1 null mice could not express osterix (62). Nishio et al. further proved that osterix acts downstream of RUNX2 to control the differentiation of osteoblasts (64). Therefore, RUNX2 and osterix are important osteogenic factors and regulate the development and differentiation of osteoblasts. Type I collagen is associated with bone structure and strength, accounting for 20% of the bone matrix. COL1A1 and COL1A2 are the encoding genes of type I collagen (65). Studies demonstrated that COL1A1 is linked to osteoporosis by regulating bone mineral density (66–68), and mutations in the COL1A1 gene can cause osteogenesis imperfecta (65, 69, 70). Furthermore, researchers found that osterix can induce the expression of COL1A1 (71). As expected, our data showed that CIHH treatment could increase the expression of RUNX2, osterix, and type I collagen. These suggested that CIHH could accelerate the program of osteoblastic differentiation and promote fracture healing.

In conclusion, CIHH treatment was able to enhance fracture healing, as proved by increasing bone formation, bone mass, and bone strength. Further, the mechanism by which CIHH promoted bone repair involved enhancing the expression of HIF-1α associated signaling pathways. These results support the therapeutic potential of CIHH to enhance open fracture healing.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article /supplementary materials. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The animal study was reviewed and approved by the Ethics Committee of Hebei Medical University.

AUTHOR CONTRIBUTIONS

LiZ conducted the experiments, wrote the manuscript, and analyzed the data. LJ, JG, and KB contributed to the experiments and data analysis. ZH and YZ conducted the micro-CT and X-ray detection. ZH guided the experiments and polished the language. LipZ designed the experiments and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

The study was supported by the National Key R&D Program of China (Grant No. 2019YFC0120600).

REFERENCES

1. Baker CE, Moore-Lotridge SN, Hysong AA, Posey SL, Robinette JP, Blum DM, et al. Bone Fracture Acute Phase Response-A Unifying Theory of Fracture Repair: Clinical and Scientific Implications. *Clin Rev Bone Mineral Metab* (2018) 16(4):142–58. doi: 10.1007/s12188-018-9256-x

2. Giannoudis PV, Einhorn TA, Marsh D. Fracture healing: The diamond concept. *Injury* (2007) 38:S3–6. doi: 10.1016/S0020-1383(08)70003-2

3. Morgan EF, Salisbury Palomares KT, Gleason RE, Bellin DL, Chien KB, Unnikrishnan GU, et al. Correlations between local strains and tissue phenotypes in an experimental model of skeletal healing. *J Biomechanics* (2010) 43(12):2418–24. doi: 10.1016/j.jbiomech.2010.04.019

4. Olerud S, Stromberg L. Intramedullary reaming and nailing: its early effects on cortical bone vasculization. *Orthopedics* (1986) 9(9):1204–8. doi: 10.3928/0147-7447-19860901-06

5. Wallace AL, Draper ER, Strachan RK, McCarthy ID, Hughes SP. The vascular response to fracture micromovement. *Clin Orthopaedics Related Res* (1994) 301:281–90.

6. Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and interventions. *Nat Rev Rheumatol* (2015) 11(1):45–54. doi: 10.1038/nrrheum.2014.164

7. Ratko TA, Belinson SE, Samson DJ, Bonnell C, Ziegler KM, Aronson N. AHRQ Technology Assessments. In: Bone Morphogenetic Protein: The State of the Evidence of On-Label and Off-Label Use. Rockville (MD: Agency for Healthcare Research and Quality (US) (2010).

8. Govender S, Csimma C, Genant HK, Valentin-Opran A, Aity M, Arbél R, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. *J Bone Joint Surg Am Volume* (2002) 84(12):2123–34. doi: 10.2106/00004623-200212000-00001

9. Simmonds MC, Brown IV, Heirs MK, Higgins JP, Mannion RJ, Rodgers MA, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. *Ann Intern Med* (2013) 158(12):877–89. doi: 10.7326/0003-4819-158-12-201306180-00005

10. Wang Y, Newman MR, Benoit DS. Development of controlled drug delivery systems for bone fracture-targeted therapeutic delivery: A review. *Eur J Pharmaceutics Biopharm* Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik Evol (2018) 127:223–36. doi: 10.1016/j.ejpb.2018.02.023

11. Tian Y, Ma X, Yang C, Su P, Yin C, Qian AR. The Impact of Oxidative Stress on the Bone System in Response to the Space Special Environment. *Int J Mol Sci* (2017) 18(10):2132. doi: 10.3390/ijms18102132
12. Cordonnier T, Layrolle P, Gaillard J, Langonne A, Sensiebe L, Rosset P, et al. 3D environment on human mesenchymal stem cells differentiation for bone tissue engineering. *J Mater Sci Mater Med* (2010) 21(3):981–7. doi: 10.1007/s10856-009-3196-0.

13. Zhang, Y, ZhouZN. [Beneficial effects of intermittent hypobaric hypoxia on the body]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue za zhi = Chin J Appl Physiol (2012) 28(6):504–9.

14. Zhang, S, Guo Z, Yang S, Ma H, Fu C, Wang S, et al. Chronic intermittent hypobaric hypoxia protects against cerebral ischemia via modulation of mitoKATP. *Neurosci Lett* (2016) 635:8–16. doi: 10.1016/j.neulet.2016.10.025.

15. Tian YM, Guan Y, Tian SY, Yuan F, Zhang L, Zhang Y. Short-term Chronic Intermittent Hypobaric Hypoxia Alters Gut Microbiota Composition in Rats. *Biomed Environ Sci* (2018) 31(12):898–901. doi: 10.3967/bes.2018.122.

16. Cheng WJ, Liu X, Zhang L, Guo XQ, Wang FW, Zhang Y, et al. Chronic intermittent hypobaric hypoxia attenuates skeletal muscle ischemia-reperfusion injury in mice. *Life Sci* (2019) 231:116533. doi: 10.1016/j.lfs.2019.06.008.

17. Zhang, Y, Zhong N, ZhouZN. Estradiol potentiates antiarrhythmic and antioxidative effects of intermittent hypoxic rat heart. *Acta pharmacologica Sin* (2000) 21(7):609–12.

18. Zhong N, Zhang Y, Zhu HF, Wang JC, Fang QZ, ZhouZN. Myocardial capillary angiogenesis and coronary flow in ischemia tolerance rat by adaptation to intermittent high altitude hypoxia. *Acta pharmacologica Sinica* (2002) 23(4):305–10.

19. Zhong N, Zhang Y, Fang QZ, ZhouZN. Intermittent hypoxia exposure-induced heat-shock protein 70 expression increases resistance of rat heart to ischemic injury. *Acta Pharmacologica Sinica* (2000) 21(5):467–72.

20. Zhu HF, Dong JW, Zhu WZ, Ding HL, Zhou ZN. ATP-dependent potassium channels involved in the cardiac protection induced by intermittent hypoxia against ischemia/reperfusion injury. *Life Sci* (2003) 73(10):1275–87. doi: 10.1016/s0024-3205(03)00429-6.

21. Zhu WZ, Xie Y, Chen L, Yang HT, Zhou ZN. Intermittent high altitude hypoxia inhibits opening of mitochondrial permeability transition pores by reperfusion injury. *J Mol Cell Cardiol* (2006) 40(1):96–106. doi: 10.1016/j.yjmcc.2005.09.016.

22. Tian YM, Guan Y, Li N, Ma HJ, Zhang L, Wang S, et al. Chronic intermittent hypobaric hypoxia ameliorates diabetic nephropathy by enhancing HIF1 signaling in rats. *Diabetes Res Clin Pract* (2016) 118:90–7. doi: 10.1016/j.diabres.2016.06.021.

23. Yuan F, Teng X, Guo Z, Zhou JJ, Zhang Y, Wang S. Chronic intermittent hypobaric hypoxia ameliorates endoplasmic reticulum stress mediated liver damage induced by fructose in rats. *Life Sci* (2015) 121:40–5. doi: 10.1016/j.lfs.2014.11.019.

24. Guan Y, Li N, Tian YM, Zhang L, Ma HJ, Malov LN, et al. Chronic intermittent hypobaric hypoxia antagonizes renal vascular hypertension by enhancement of vasorelaxation via activating BKCa. *Life Sci* (2016) 157:74–81. doi: 10.1016/j.lfs.2016.05.028.

25. Zhou JJ, Wei Y, Zhang L, Zhang J, Guo LY, Gao C, et al. Chronic intermittent hypobaric hypoxia prevents cardiac dysfunction through enhancing antioxidation in fructose-fed rats. *Can J Physiol Pharmacol* (2013) 91(5):3327–7. doi: 10.1139/cjpp-2012-0059.

26. Li N, Guan Y, Tian YM, Ma HJ, Zhang X, Zhang Y, et al. Chronic Intermittent Hypobaric Hypoxia Ameliorates Renal Vascular Hypertension Through Up-regulating NOS in Nucleus Tractus Solitarii. *Neurosci Bull* (2019) 35(1):79–90. doi: 10.1007/s12264-018-0330-x.

27. Shi M, Cui F, Liu AJ, Ma HJ, Cheng M, Song SX, et al. The protective effects of chronic intermittent hypobaric hypoxia pretreatment against collagen-induced arthritis in rats. *J Inflammation (London England)* (2015) 12:23. doi: 10.1186/s12950-015-0068-1.

28. Yang J, Zhang L, Wang H, Guo Z, Liu Y, Zhang Y, et al. Protective Effects of Chronic Intermittent Hypobaric Hypoxia Pretreatment against Aplastic Anemia through Improving the Adhesiveness and Stress of Mesenchymal Stem Cells in Rats. *Stem Cells Int* (2017) 2017:5706193. doi: 10.1155/2017/5706193.

29. Zhu XH, Yan HC, Zhang J, Qu HD, Qiu XS, Chen L, et al. Intermittent hypoxia promotes hippocampal neurogenesis and produces antidepressant-like effects in adult rats. *J Neurosci Off J Soc Neurosci* (2010) 30(38):12653–63. doi: 10.1523/jneurosci.6411-09.2010.
50. Keramaris NC, Calori GM, Nikolaou VS, Schemitsch EH, Giannoudis PV. Fracture vascul arity and bone healing: a systematic review of the role of VEGF. Injury (2008) 39(Suppl 2):S45–57. doi: 10.1016/s0020-1383(08)70015-9

51. Newman PJ, Newman DK. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol (2003) 23(6):953–64. doi: 10.1161/01.atv.0000071347.69358.d9

52. Cao G, O’Brien CD, Zhou Z, Sanders SM, Greenbaum IN, Makrigiannakis A, et al. Involvement of PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am J Physiol Cell Physiol (2002) 282(5):C1181–90. doi: 10.1152/ajpcell.00524.2001

53. Dar A, Goichberg P, Shinder V, Kalinkovich A, Kollet O, Netzer N, et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol (2005) 6(10):1038–46. doi: 10.1038/ni1251

54. Liu X, Zhou C, Li Y, Ji Y, Xu G, Wang X, et al. SDF-1 promotes endochondral bone repair during fracture healing at the traumatic brain injury condition. PloS One (2013) 8(1):e54077. doi: 10.1371/journal.pone.0054077

55. Xue Y, Li Z, Wang Y, Zhu X, Hu R, Xu W. Role of the HIF1alpha/SDFI/CXCR4 signaling axis in accelerated fracture healing after craniocerebral injury. Mol Med Rep (2020) 22(4):2767–74. doi: 10.3892/mmr.2020.11361

56. Komori T. Molecular Mechanism of Runx2-Dependent Bone Development. Mol Cells (2020) 43(2):168–75. doi: 10.14348/molcells.2019.0244

57. Kim HJ, Kim WJ, Ryoo HM. Post-Translational Regulations of Transcriptional Activity of RUNX2. Mol Cells (2019) 43(2):160–7. doi: 10.14348/molcells.2019.0247

58. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 89(5):755–64. doi: 10.1016/S0092-8674(00)80258-5

59. Enomoto H, Furuichi T, Zanma A, Yamana K, Yoshida C, Sumitani S, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 108(1):17–29. doi: 10.1016/S0092-8674(01)00622-5

52. Zhang et al. CIHH Promote Bone Fracture Healing

53. Oh JH, Park SY, de Crombrugghe B, Kim JE. Chondrocyte-specific ablation of Osterix leads to impaired endochondral ossification. Biochem Biophys Res Commun (2012) 421(3):634–40. doi: 10.1016/j.bbrc.2012.01.064

54. Nishio Y, Dong Y, Paris M, O’Keefe RJ, Schwarz EM, Drissi H. Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene. Gene (2006) 372:62–70. doi: 10.1016/j.gene.2005.12.022

55. Augusciak-Duma A, Witecka J, Sieron AL, Janeczko M, Pietrzyk J, Ohman K, et al. Mutations in the COL1A1 and COL1A2 genes associated with osteogenesis imperfecta (OI) types I or III. Acta Biochim Pol (2018) 65(1):79–86. doi: 10.18388/abp.2017_1612

56. Stewart TL, Jin H, McGuigan FE, Albagha OM, Garcia-Giral N, Bassiti A, et al. Haplotypes defined by promoter and intron I polymorphisms of the COL1A1 gene regulate bone mineral density in women. J Clin Endocrinol Metab (2006) 91(9):3575–83. doi: 10.1210/jc.2005-2651

57. Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP, et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest (2001) 107(7):899–907. doi: 10.1172/jci10347

58. Stover DA, Verrelli BC. Comparative vertebrate evolutionary analyses of type I collagen: potential of COL1a1 gene structure and intron variation for common bone-related diseases. Mol Biol Evol (2011) 28(1):533–42. doi: 10.1093/molbev/msq221

59. Tanner L, Vainio P, Sandell M, Laine J. Novel COL1A1 Mutation c.3290G>T Associated With Severe Form of Osteogenesis Imperfecta in a Fetus. Pediatr Dev Pathol (2017) 20(5):455–9. doi: 10.1177/1093526616686093

60. Symoens S, Steyaert W, Demuyynck L, De Paepe A, Malfer P, et al. Tissue-specific mosaicism for a lethal osteogenesis imperfecta COL1A1 mutation causes mild OI/EDS overlap syndrome. Am J Med Genet A (2017) 173(4):1047–50. doi: 10.1002/ajmg.a.38135

61. Ortuno MJ, Susperregui AR, Artigas N, Rosa JL, Ventura F. Osterix induces Col1a1 gene expression through binding to Sp1 sites in the bone enhancer and proximal promoter regions. Bone (2013) 52(2):548–56. doi: 10.1016/j.bone.2012.11.007

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Jin, Guo, Bao, Hu, Zhang, Hou and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.